Related Experiment Video
Updated: Aug 25, 2025
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.9K
Novel approaches to antiplatelet therapy
Paolo Gresele1, Stefania Momi1
1Department of Medicine and Surgery, Division of Internal and Cardiovascular Medicine, University of Perugia, Perugia, Italy.
Biochemical Pharmacology
|October 15, 2022
Summary
New antiplatelet agents aim to improve efficacy and reduce bleeding complications in preventing thrombotic events like heart attack and stroke. Current and novel drugs are reviewed for their potential to selectively target pathological thrombus formation without hindering hemostasis.
Area of Science:
- Cardiovascular Pharmacology
- Hematology
- Thrombosis Research
Background:
- Platelets are key effectors in thrombotic events at ruptured atherosclerotic plaques.
- Antiplatelet agents are crucial for preventing myocardial infarction, ischemic stroke, and critical limb ischemia.
- Existing antiplatelet therapies face challenges of insufficient efficacy and hemorrhagic complications.
Purpose of the Study:
- To review current pharmacologic approaches to platelet inhibition.
- To discuss novel antiplatelet agents in development targeting new pathways.
- To evaluate the potential of new agents in preventing pathological thrombus formation.
Main Methods:
- Review of pharmacologic strategies for platelet inhibition.
- Analysis of in vitro platelet activation studies.
- Evaluation of thrombosis models in animal and human studies.
Main Results:
- Significant progress has been made in antiplatelet drug development.
- Novel targets and agents, including GPVI antagonism and PI3K inhibition, are in clinical testing.
- Current agents do not perfectly balance antithrombotic efficacy with hemostasis.
Conclusions:
- New antiplatelet agents offer promise for improved cardiovascular event prevention.
- The development of agents that selectively target pathological thrombosis is ongoing.
- Achieving selective inhibition without compromising hemostasis remains a critical goal for future antithrombotic therapies.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
614
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
614
01:27Peripheral Artery Disease III: Interprofessional Care
21
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
21
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:29Venous Thrombosis III: Interprofessional Care
18
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
18
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
854
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
854
01:26Angina IV: Management
16
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
16